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Abstract  Derivatives of N,N-diallyltryptamine (DALT) can be classified as new psychoactive 
substances. Biotransformation and detectability of 5-fluoro-DALT (5-F-DALT), 7-methyl-DALT 
(7-Me-DALT), and 5,6-methylenedioxy-DALT (5,6-MD-DALT) are described here. Their 
metabolites detected in rat urine and pooled human liver microsomes were identified by liquid 
chromatography (LC)-high resolution (HR)-tandem mass spectrometry (MS/MS). In addition, the 
human cytochrome-P450 (CYP) isoenzymes involved in the main metabolic steps were identified 
and detectability tested in urine by the authors’ urine screening approaches using GC-MS, LC-MSn, 
or LC-HR-MS/MS. Aromatic and aliphatic hydroxylations, N-dealkylation, N-oxidation, and 
combinations could be proposed for all compounds as main pathways. Carboxylation after initial 
hydroxylation of the methyl group could also be detected for 7-Me-DALT and O-demethylenation 
was observed for 5,6-MD-DALT. All phase I metabolites were extensively glucuronidated or 
sulfated. Initial phase I reactions were catalyzed by CYP1A2, CYP2B6, CYP2C9, CYP2C19, 
CYP2D6, CYP3A4, and CYP3A5. Rat urine samples were analyzed following two different low 
dose administrations. GC-MS was not able to monitor consumption reliably, but all three drugs are 
predicted to be detectable in cases of overdose. The LC-MSn and LC-HR-MS/MS approaches were 
suitable for detect an intake of all three compounds mainly via their metabolites. However, after the 
lowest dose, a reliable monitoring could only be achieved for 5-F-DALT via LC-MSn and 
LC-HR-MS/MS and for 7-Me-DALT via LC-HR-MS/MS. The most abundant targets in both 
LC-MS screenings were one of two hydroxy-aryl metabolites and both corresponding glucuronides 
for 5-F-DALT, one N-deallyl hydroxy-aryl, the carboxy, and one dihydroxy-aryl metabolite for 
7-Me-DALT, and the demethylenyl metabolite, its oxo metabolite, and glucuronide for 
5,6-MD-DALT. 
 
Keywords tryptamine derivatives; 5-F-DALT; 7-Me-DALT; 5,6-MD-DALT; metabolism; 
screening
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Introduction 
 
New psychoactive substances (NPS) represent an emerging issue worldwide. During the last years 
the number of reported NPS raised continuously [1-4]. According to the World Drug Report 2016 
[4], synthetic tryptamines are still among the most commonly reported NPS besides synthetic 
cannabinoids, phenethylamines, synthetic cathinones, and piperazines. Both classic tryptamine 
psychedelics such as N,N-dimethyltryptamine (DMT) but also synthetic tryptamine-based “research 
chemicals” have been popular. [5, 6]. N,N-Diallyltryptamine (DALT) derivatives represent an 
important group with 5-methoxy-DALT (5-MeO-DALT) being the most often reported example 
[7-9]. As such drugs may become controlled the creation of new substances with similar chemical 
structures and effects is aimed at circumventing legislative restrictions [5], which leads to 
significant challenges for drug testing laboratories in the attempt to be kept up-to-date with 
analytical methods and reference data [10, 11]. One prerequisite is the knowledge of the NPS 
metabolism particularly for urine drug testing. Such data can only be generated if reference 
standards are available. One way to get them is to wait until their appearance on the drugs of abuse 
market or to synthesize potential derivatives in anticipation of future occurrences on the market. 
In a previous study, DALT and 5-MeO-DALT were investigated in detail concerning 
metabolism and urinalysis [9]. The present study describes the biotransformation and detectability 
of three ring substituted DALT derivatives 5-fluoro-DALT (5-F-DALT), 7-methyl-DALT 
(7-Me-DALT), and 5,6-methylenedioxy-DALT (5,6-MD-DALT), which were synthesized in 
advance of potential distribution as NPS [12]. As Cozzi and Daley [13] described pharmacological 
potency for 5-substitued DALTs and Wagmann et al. the inhibition of the monoamine oxidase A 
(publication in preparation) it can be assumed that such compounds will appear once on the drugs 
of abuse market. So far, only spectroscopic data [14] and an LC-MSn approach for qualitative and 
quantitative of tryptamines in plasma and urine covering only the parent drugs [15] were published. 
In this investigation, it was aimed to i) identify the phase I and II metabolites in rat urine, ii) 
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confirm the phase I metabolites in pooled human liver microsomes (pHLM) by liquid 
chromatography (LC)-high resolution (HR)-MS/MS, iii) identify the human cytochrome-P450 
(CYP) isoenzymes involved in the main metabolic steps, and iv) to test the detectability in urine by 
the authors’ urine screening approaches (SUSA) using GC-MS [16], LC-MSn [17], or 
LC-HR-MS/MS [18], respectively. With the help of the presented data and procedures, these 
compounds should be detected in potential clinical or forensic cases. 
 
 
Experimental 
 
Chemicals and reagents 
 
5-F-DALT, 7-Me-DALT, 5,6-MD-DALT, and DALT-d4 were synthesized as published previously 
[12], isocitrate and isocitrate dehydrogenase were purchased from Sigma (Taufkirchen, Germany), 
NADP+ from Biomol (Hamburg, Germany), acetonitrile (LC-MS grade), ammonium formate 
(analytical grade), formic acid (LC-MS grade), methanol (LC-MS grade), and all other chemicals 
and biochemicals from VWR (Darmstadt, Germany). The baculovirus-infected insect cell 
microsomes (Supersomes) containing 1 nmol/mL of human cDNA-expressed CYP1A2, CYP2A6, 
CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 (2 nmol/mL), CYP3A4, or CYP3A5 
(2 nmol/mL), and pooled human liver microsomes (pHLM, 20 mg microsomal protein/mL, 400 
pmol total CYP/mg protein) were obtained from BD Biosciences (Heidelberg, Germany). After 
delivery, the microsomes were thawed at 37 °C, divided into aliquots, snap-frozen in liquid 
nitrogen, and stored at -80 °C until use.  
 
Urine samples 
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Investigations were performed as usual [9] with rat urine samples taken from male Wistar rats 
(Charles River, Sulzfeld, Germany) for toxicological diagnostic reasons. The test drugs were 
administered once in an aqueous suspension by gastric intubation in a single 20 mg/kg body mass 
(BM) dose for the identification of the metabolites and once in a single 1 or 0.1 mg/kg BM dose for 
toxicological analysis according to the German animal protection act. The rats were housed in 
metabolism cages for 24 h, having water ad libitum. Urine was collected separately from feces over 
a 24-h period. Blank urine samples were collected before drug administration to confirm the 
absence of interfering compounds. The samples were directly analyzed and then stored at -20 °C. 
 
Sample preparation for identification of phase I and II metabolites by LC-HR-MS/MS 
 
As described previously [9, 19], 500 µL of acetonitrile was added to 100 µL of urine. The mixture 
was shaken on a rotary shaker for 2 min. After centrifugation for 2 min at 10,000×g, 500 µL was 
transferred into a glass vial and evaporated to dryness under a gentle stream of nitrogen at 70 °C. 
The residue was dissolved in 50 µL of methanol. A 10-µL aliquot of each extract was then injected 
onto the LC-HR-MS/MS system. 
 
Microsomal incubations for pHLM and initial CYP activity screening studies 
 
Conditions for performing the microsomal incubations were published previously [9, 20]. Briefly, 
compounds (50 µmol/L each) were incubated with the CYP isoenzymes (50 pmol/mL, each) 
CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, 
CYP3A5, or pHLM (1 mg protein/mL) for 30 min. Reactions were initiated by addition of the 
substrate and stopped with 50 µL of ice-cold acetonitrile containing DALT-d4 (1 mg/L) as internal 
standard. The solution was centrifuged for 2 min at 10,000×g, 50 µL of the supernatant phase were 
transferred to a glass vial and a 10-µL aliquot injected onto the LC-HR-MS/MS system. 
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LC-HR-MS/MS apparatus for identification of metabolites in urine and microsomal incubations 
 
According to published procedures [9, 18], the extracts were analyzed using a Accela LC system 
consisting of an HTC PAL autosampler, a degasser, two 1250 quaternary pumps, an Aria Transcend 
TLX-I HTLC system, and a valve interface module with built-in switching valves, all controlled by 
the Aria software version 1.6.3, coupled to a Q-Exactive system equipped with a heated 
electrospray ionization (HESI)-II source and Xcalibur 2.2 SP1.48 software (all of ThermoFisher, 
Dreieich, Germany). Mass calibration was done according to the manufacturer’s recommendations 
every 72 h using external mass calibration. The LC and MS conditions were according to Helfer et 
al. [18] and set as follows: a ThermoFisher Accucore PhenylHexyl column (100 mm × 2.1 mm I.D., 
2.6 µm), guarded by an UHP filter cart (0.5 µm). Chromatography was performed at 35 °C 
maintained by an analytical column heater (HotDog 5090, Prolab, Reinach, Switzerland). The 
mobile phases consisted of 2 mM aqueous ammonium formate plus 0.1% formic acid (pH 3, eluent 
A) and 2 mM aqueous ammonium formate with acetonitrile:methanol (1:1, v/v; 1% water) plus 
0.1% formic acid (eluent B). The flow rate was set to 0.5 mL/min for 10 min and 0.8 mL/min from 
10-13.5 min. The gradient was programmed as follows: 0-1 min 99% A, 1-10 min to 1% A, 10-11.5 
min hold 1% A, 11.5 - 13.5 min hold 99% A. The HESI-II source conditions were as follows: 
heater temperature, 320 °C; sheath gas, 60 arbitrary units (AU); auxiliary gas, 10 AU; spray 
voltage, 3.00 kV; capillary temperature, 320 °C; and S-lens RF level, 60.0. Mass spectrometry was 
performed in positive ionization mode using full scan mode and a subsequent data-dependent 
acquisition (DDA) mode. The settings for the full scan mode were as follows: scan range, m/z 
130-1000; resolution, 35,000; microscans, 1; automatic gain control (AGC) target, 1e6; and 
maximum injection time (IT), 120 ms. The settings for the DDA mode were as follows: resolution, 
17,500; microscans, 1; AGC target, 2e5; maximum IT, 250 ms; loop count, 5; isolation window, 
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m/z 1.0; high collision dissociation (HCD) cell stepped normalized collision energy (NCE), 17.5, 
35, and 52.5%; spectrum data type, profile; intensity threshold, 4.0e3; dynamic exclusion, 8.0 s. 
 
GC-MS SUSA 
 
According to published procedures [9, 16], the urine sample (5 mL) was divided into two aliquots 
where one part was submitted to acid hydrolysis followed by extraction of the combined parts with 
a dichloromethane-isopropanol-ethyl acetate mixture. After evaporation, the residue was acetylated 
with an acetic anhydride-pyridine mixture under microwave irradiation, again evaporated and 
reconstituted in 100 µL of methanol. A 1-µL aliquot was injected onto the GC-MS system. This 
consisted of a Hewlett Packard (HP, Agilent, Waldbronn, Germany) 5890 Series II gas 
chromatograph combined with an HP 5972A MSD mass spectrometer and an HP MS ChemStation 
(DOS series) with HP G1034C software version C03.00. The GC conditions were as follows: 
splitless injection mode; column, ThermoFisher TG-1MS capillary (12 m x 0.2 mm I.D.); 
cross-linked methyl silicone, 330 nm film thickness; injection port temperature, 280 °C; carrier gas, 
helium; flow rate, 1 mL/min; column temperature, programmed from 100 to 310 °C at 30 °C/min; 
initial time, 2 min; final time, 5 min. The MS conditions were as follows: full scan mode, m/z 
50-550; electron ionization (EI) mode, ionization energy, 70 eV; ion source temperature, 220 °C; 
and capillary direct interface, 280 °C. 
The full scan data files were evaluated by the automated mass spectral deconvolution and 
identification system (AMDIS; http://chemdata.nist.gov/mass-spc/amdis/) in simple mode. The 
Maurer/Pfleger/Weber MPW_2016 library [21] was used as target library. The deconvolution 
parameter settings were as follows [22]: width, 32; adjacent peak subtraction, 2; resolution, high; 
sensitivity, very high; shape requirements, low; minimum match factor, 50. 
 
LC-MSn SUSA 
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The workup was identical to the procedure described above for identification of the metabolites. 
Analysis was performed using a LXQ linear ion trap MS equipped with an HESI-II source and 
coupled to an Accela LC system (all from ThermoFisher). The LC and the MS settings were 
described elsewhere [9, 19]. Briefly, DDA was conducted on precursor ions selected from MS1: 
MS1 was performed in the full scan mode (m/z 100-800) and MS2 and MS3 were performed in the 
DDA mode. ThermoFisher Xcalibur 2.2 SP1.48 software was used for data acquisition, NIST MS 
Search 2.0 (National Institute of Standards and Technology, Gaithersburg, MD, USA) for library 
generation, ThermoFisher ToxID 2.1.1 for automatic target screening in the MS2 screening mode. 
The settings were as follows: retention time (RT) window, 20 min; RT, 0.1 min; signal threshold, 
100; search index, 600; and reverse search index, 700. ToxID was run automatically after file 
acquisition using a Xcalibur processing method starting the software tool. The target library was a 
modified and updated version of the Maurer/Wissenbach/Weber MWW_2014 [23].  
 
LC-HR-MS/MS SUSA 
 
The workup and the LC-HR-MS/MS method were the same as described above for identification of 
the metabolites. For data evaluation, ThermoFisher TraceFinder Clinical Research 3.2 software was 
used as described by Helfer et al. [18] with the target library of Maurer et al. (Maurer HH, Meyer 
MR, Helfer AG, Weber AA (2016) Maurer/Meyer/Helfer/Weber MMHW LC-HR-MS/MS library 
of drugs, poisons, and their metabolites. Wiley-VCH, Weinheim (Germany), in preparation).  
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Results and discussion 
 
Phase I and phase II metabolites identified by LC-HR-MS/MS 
 
In analogy to a previous study [9], correlation of the MS/MS spectra of the parent compounds and 
their metabolites allowed deducing the metabolite structures considering established rules [24]. The 
spectra are supplied as electronic supplementary material in Fig. S1, S2, and S3, those of the phase 
II metabolites in Fig. S4, S5, and S6 for 5-F-DALT, 7-Me-DALT, and 5,6-MD-DALT, 
respectively. The figures contain also the proposed chemical structures, accurate masses of the ions, 
calculated elemental formulas, and mass error values. 
 
Fragmentation patterns proposed for identification of the phase I metabolites by LC-HR-MS/MS 
 
The basic structure was divided into three sections (Fig. 1) for better description of positions: the 
aromatic ring (section 1), the ethyl spacer (section 2), and the N,N-diallylamine (section 3). In the 
following chapters, important mass spectra fragmentation patterns of 5-F-DALT, 7-Me-DALT, 
5,6-MD-DALT, and their phase I metabolites will be discussed in detail. All masses within 
subsequent paragraphs are the calculated, exact masses. 
 
5-F-DALT 
 
Figure S1, no. 1 shows the spectrum of the parent compound with the protonated molecular ion of 
m/z 259.1605 (C16H20N2F+) and characteristic fragment ions of m/z 162.0714 (C10H9NF+) and m/z 
110.0964 (C7H12N+), representing the ethyl indole residue (section 1+2) and the 
N,N-diallylmethanimine residue (section 3) following typical α-cleavage [25].  
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Specific shifts could be observed for each section. If the structure in section 3 was 
unmodified fragment ions of m/z 110.0964 (C7H12N+) could be observed (nos. 7-10, and 12-13 in 
Fig. S1) and if N-deallylated (- 40.0313 u) fragment ions of m/z 70.0651 (C4H8N+) were detected 
(nos. 3-5). If the structures in sections 1 and 2 were unmodified, fragment ions of m/z 162.0714 
(C10H9NF+) were observed (nos. 3 and 11), if mono-hydroxylated (+ 15.9949 u) ions of m/z 
178.0662 (C10H9ONF+; nos. 2, 4, 5, 7, and 8), or if dihydroxylated (+ 31.9898 u) ions of m/z 
194.0612 (C10H9O2NF+; nos. 9 and 10) occurred. If the structure in section 1 was modified 
fragment ions of m/z 164.0506 (C9H7ONF+; no. 6) or m/z 150.0714 (C9H9NF+; nos. 2, 4, 5, 7, and 8) 
could be detected after mono-hydroxylation, fragment ions of m/z 166.0299 (C8H5O2NF+; nos. 9 
and 10) after dihydroxylation, or fragment ions of m/z 182.0248 (C8H5O3NF+; nos. 12-13) after 
trihydroxylation.  
For mono-hydroxylations, the protonated molecules of m/z 275.1554 (C16H20ON2F+) were 
observed and revealed two isomeric aryl-hydroxy metabolites (nos. 7 and 8). For the three 
dihydroxylated metabolites, the protonated molecules of m/z 291.1503 (C16H20O2N2F+) led to two 
isomeric aryl-dihydroxy metabolites (nos. 9 and 10) and one N-oxide with additional hydroxylation 
in section 3 (no. 11). Identification was proposed by the fragment ions of m/z 142.0863 
(C7H12O2N+: 110.0964 + 31.9899 u) and m/z 100.0757 (C5H10ON+), which represented 
dihydroxylated N,N-diallylmethanimine and mono-hydroxylated N-allyl-N,N-bis-methylamine, 
respectively. These fragment ions led to the assumption that both hydroxy groups were in section 3 
consistent with observations reported by Michely et al. [9], whereby one oxygen was assumed to 
represent an N-oxide. For confirmation, a typical property of N-oxides, namely showing a longer 
RT compared to its non-oxidized precursor on reversed phase columns, was considered [9]. 
Unfortunately, the corresponding precursor could not be detected, but the long RT (4.3 min) could 
be compared to those of all other hydroxy, dihydroxy, and trihydroxy metabolites (RT between 2.0 
and 4.1 min) that supported the suggested N-oxide detection. Trihydroxylations led to protonated 
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molecules of m/z 307.1452 (C16H20O3N2F+) with two detected isomeric spectra. As discussed 
above, they could be proposed as aryl-trihydroxy metabolites (nos. 12 and 13).  
Considering oxidation, a protonated molecule of m/z 273.1398 (C16H18ON2F+) showed a 
spectrum (no. 6) with different fragmentation pattern compared to other spectra. The fragment ions 
of m/z 232.1006 (C13H13ON2F+•) and m/z 191.0615 (C10H8ON2F+) represented the loss of both allyl 
groups followed by loss of hydrocyanic acid, respectively. This fragmentation pattern could be 
explained by ring closure in accordance to the metabolism of DALT and 5-MeO-DALT [9]. The 
initial step for this metabolite might have reflected a hydroxylation in the amine α-position, leading 
to an unstable hemiaminal. This could either degrade, oxidize to an amide, or engage in 
nucleophilic attack of the indole 2-position with resulting ring closure. 
Metabolic N-dealkylation (no. 3) led after protonation to a molecule of m/z 219.1292 
(C13H16N2F+), further aryl-hydroxylation (nos. 4 and 5) to two protonated molecules of m/z 
235.1241 (C14H16ON2F+), and additional subsequent N-dealkylation to a N,N-bis-deallyl 
aryl-hydroxy metabolite (no. 2) with a protonated molecule of m/z 195.0928 (C10H12ON2F+). 
 
7-Me-DALT 
 
Figure S2, no. 14 shows the spectrum of the parent compound with the protonated molecular ion of 
m/z 255.1856 (C17H23N2+) and the characteristic fragment pattern is given by fragment ions of m/z 
158.0964 (C11H12N+) and m/z 143.0730 (C10H9N+•) representing the ethyl or methyl indole residue 
(sections 1+2), and of m/z 110.0964 (C7H12N+), again representing the N,N-diallylmethanimine 
residue (section 3). 
If the structure in section 3 was unmodified, fragment ions could be observed of m/z 110.0964 
(C7H12N+; nos. 18, 19, 21-23, 25, 26, and 28 in Fig. S2), if N-deallylated ions of m/z 70.0651 
(C4H8N+; nos. 15-17). If the structures in sections 1 and 2 were unmodified, fragment ions of m/z 
158.0964 (C11H12N+) and m/z 143.0730 (C10H9N+•; nos. 15, 20, 24, and 27) appeared, if 
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mono-hydroxylated shifts to fragment ions of m/z 174.0913 (C11H12ON+; nos. 16-20) and/or m/z 
159.0679 (C10H9ON+) were observed (nos. 16, 18, and 19), if dihydroxylated, ions of m/z 190.0863 
(C11H12O2N+; nos. 22 and 23) and/or m/z 162.0550 (C9H8O2N+; no. 23), or if trihydroxylated, ions 
of m/z 206.0812 (C11H12O3N+; no. 26) appeared. Due to the fact that hydroxylation of the structure 
in in section 2 led to additional high abundant water losses (- 18.0106 u), the presence or absence of 
corresponding fragment ions led to the refined position of hydroxylations in section 2 or 1, 
respectively. After proposed water losses, fragment ions were detected of m/z 156.0807 (C11H10N+: 
174.0913 - 18.0106 u; no. 17), m/z 172.0757 (C11H10ON+: 190.0863 - 18.0106 u; no. 22), or m/z 
188.0706 (C11H10O2N+: 206.0812 - 18.0106 u; no. 26). After carboxylation of the methyl group in 
section 1, fragment ions of m/z 188.0706 (C11H10O2N+; no. 21) occurred. After subsequent 
mono-hydroxylation (no. 25), corresponding fragment ions could be observed of m/z 204.0656 
(C11H10O3N+) or after subsequent dihydroxylation (no. 28) of m/z 220.0604 (C11H10O4N+). It should 
be mentioned that these fragment ions could also represent ethyl indole structures following water 
losses as already described, but could be distinguished by considering the precursor molecules and 
the lack of corresponding fragment ions shifted by +18.0106 u (+ H2O).  
After mono-hydroxylation, three protonated molecules of m/z 271.1804 (C17H23ON2+) could 
be detected. Two of them were proposed to be aryl-hydroxy metabolites (nos. 18 and 19) and the 
third isomer might have reflected the N-oxide species (no. 20) based on increased retention (4.9 
min) compared to the parent compound (4.7 min) as described above. Dihydroxylation led to three 
isomers with protonated molecules of m/z 287.1754 (C17H23O2N2+), whereby one isomer was 
proposed to be an aryl-hydroxy metabolite with additional hydroxylation in section 2 (no. 22), one 
isomer to be an aryl-dihydroxy metabolite (no. 23), and one to be an N-oxide with additional 
hydroxylation in section 3 (no. 24), identified by the fragment ion of m/z 142.0863 (C7H12O2N+) as 
already described above and by longer RT (4.5 min) compared to the other mono- and 
multi-hydroxy metabolites (RT between 2.9 and 3.9 min). After trihydroxylation, two isomers with 
protonated molecules of m/z 303.1703 (C17H23O3N2+) were detected, whereby one isomer was 
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thought to be an aryl-dihydroxy metabolite with additional hydroxylation in section 2 (no. 26), 
whereas the other was suggested to be an N-oxide with additional dihydroxylation in section 3 (no. 
27), identified by fragment ion of m/z 158.0957 (C11H12N+), representing unmodified sections 1 and 
2. Similarly, the increased RT of 4.7 min was consistent with the proposed N-oxidation. Finally, 
one isomer after fourfold hydroxylation could be detected with the spectrum no. 29 showing a 
protonated molecule of m/z 319.1652 (C17H23O4N2+) and a slightly different fragmentation pattern. 
The fragment ion of m/z 144.1019 (C7H14O2N+: 110.0964 + 31.9899 + 2.0156 u) represented a 
dihydroxylated N,N-diallylmethanamine (section 3), but with a shift of two hydrogens (+ 2.0156 u) 
compared to the fragment ion of m/z 142.0863 (C7H12O2N+) described for spectrum no 24. In 
addition, the fragment ion of m/z 188.0706 (C11H10O2N+) occurred, representing the ethyl indole 
structure (section 1+2), but with further double bond in section 2. This led to the assumption that 
two hydroxy groups were positioned in section 1 and two in section 3, respectively. 
Furthermore, the carboxylation following initial hydroxylation at the methyl group in section 
1 with further oxidation to a carboxy group (no. 21) could be detected with a protonated molecule 
of m/z 285.1598 (C17H21O2N2+). The fragment ion of m/z 188.0706 (C11H10O2N+) represented the 
ethyl indole structure with the carboxy substituent as described above and the fragment ion of m/z 
170.0600 (C11H8ON+) represented the same structure after subsequent loss of water. Similar 
fragmentation pattern for carboxy substituents at aromatic systems had already been described in 
previous studies [26] on the NPS 4-methyl-N-ethylmethcathinone (4-MEC). Furthermore, 
subsequent mono-hydroxylation (no. 25) and dihydroxylation (no. 28) in section 1 led to spectra 
with protonated molecules of m/z 301.1547 (C17H21O3N2+) or m/z 317.1496 (C17H21O4N2+) and 
shifts of +15.9949 u for one oxygen to m/z 186.0550 (C11H8O2N+) or 202.0499 (C11H8O3N+), 
respectively. An additional fragment ion of m/z 192.0291 (C9H6O4N+) could be observed in 
spectrum no. 28 representing section 1. 
N-Dealkylation (no. 15) was detected with a protonated molecule of m/z 215.1543 
(C14H19N2+) and after further hydroxylation in two isomeric metabolites with protonated molecules 
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of m/z 231.1492 (C14H19ON2+). One of these isomers was hydroxylated in section 2 (no. 17). The 
second isomer showed an additional fragment ion of m/z 162.0913 (C10H12ON+), which represented 
hydroxy methyl indole with hydroxylation taking place in section 1 (no. 16). 
 
5,6-MD-DALT 
 
Figure S3, no. 30 shows the spectrum of the parent compound with the protonated molecule of m/z 
285.1598 (C17H21O2N2+) and the characteristic fragmentation pattern with the fragment ions of m/z 
188.0706 (C11H10O2N+) representing the ethyl indole residue (section 1+2), m/z 158.0600 
(C10H8ON+) after cleavage of formaldehyde (- 30.0106), and m/z 110.0964 (C7H12N+) for section 3. 
Unmodified section 3 led to fragment ions of m/z 110.0964 (C7H12N+; nos. 33-37 in Fig. S3) 
and if N-deallylated (- 40.0313 u) of m/z 70.0651 (C4H8N+; nos. 31 and 32), unmodified sections 1 
and 2 led to fragment ions of m/z 188.0706 (C11H10O2N+) and m/z 158.0600 (C10H8ON+; nos. 31, 
36, 38, and 39). If section 1 and 2 were mono-hydroxylated (nos. 32 and 35) fragment ions of m/z 
204.0656 (C11H10O3N+: 188.0706 + 15.9949 u), m/z 174.0550 (C10H8O2N+: 158.0600 + 15.9949 u), 
m/z 176.0342 (C9H6O3N+), and m/z 146.0600 (C9H8ON+) could be observed.  
After mono-hydroxylation, two isomeric metabolites were detected with protonated 
molecules of m/z 301.1547 (C17H21O3N2+). One isomer presumably reflected the presence of an 
aryl-hydroxy metabolite (no. 35) whereas the other isomer was identified as an N-oxide (no. 36) 
with longer RT (4.5 min) than the parent compound (4.3 min). After dihydroxylation, two spectra 
with protonated molecules of m/z 317.1496 (C17H21O4N2+) were detected, one proposed 
aryl-dihydroxy metabolite (no. 37) and one N-oxide with further hydroxylation in section 3 (no. 
38). Furthermore, one spectrum with a protonated molecule of m/z 333.1440 (C17H21O5N2+) showed 
an N-oxide with further dihydroxylation in section 3 (no. 39). The spectra showed fragment ions of 
m/z 142.0863 (C7H12O2N+: 110.0964 + 31.9899 u) or m/z 158.0812 (C7H12O3N+: 110.0964 + 
47.9848 u), representing di- or trihydroxylated N,N-diallylmethanimine (section 3). N-oxidations 
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were again proposed due to long RT of 4.0 or 4.2 min compared to those of all hydroxy 
metabolites (only up to 3.6 min). A further spectrum could be detected after N-dealkylation (no. 31) 
with a protonated molecule of m/z 245.1285 (C14H17O2N2+), a fragment ion of m/z 176.0706 
(C10H10O2N+) representing the ethyl indole residue with two hydroxy groups, which may be formed 
after cleavage of the methylene group. Furthermore, a fragment ion of m/z 146.0600 (C9H8ON+) 
could be observed, what was already described for metabolites with mono-hydroxylated section 1, 
what seemed to be formed after cleavage of formaldehyde from the methylenedioxy substituent. 
One N-deallyl aryl-hydroxy metabolite (no. 32) was detected with a protonated molecule of m/z 
261.1234 (C14H17O3N2+) and fragment ions, which were already described above.  
In addition, a common metabolic step of methylenedioxy compounds was the 
demethylenation [27]. The resulting metabolite (no. 33) was detected with a protonated molecule of 
m/z 273.1598 (C16H21O2N2+). Additional hydroxylation in section 2 with subsequent oxidation led 
to a spectrum of a demethylenyl oxo metabolite (no. 34) with a protonated molecule of m/z 
287.1390 (C17H19O3N2+) and typical fragmentation pattern in contrast to those after ring closure 
(no. 6 in Fig.S1). 
 
Fragmentation patterns proposed for identification of the phase II metabolites by LC-HR-MS/MS 
 
Relevant fragmentation patterns of the mass spectra of 5-F-DALT, 7-Me-DALT, and 
5,6-MD-DALT phase II metabolites will be presented here with all masses representing the 
calculated exact masses. 
 
5-F-DALT 
 
After loss of the conjugate moiety (-79.9568 u for sulfates or -176.0321 u for glucuronides) the 
spectra showed same fragment ions corresponding to those of the underlying phase I metabolites. 
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Additional fragment ions of m/z 258.0231 (C10H9O4NFS+; nos. 4S, 5S, and 7S in Fig. S4) were 
observed for sulfates or ions of m/z 354.0984 (C16H17O7NF+; nos. 4G, 5G, 7G, and 8G) for 
glucuronides. These fragment ions represented conjugated ethyl indole parts (258.0231: 178.0662 + 
79.9568; 354.0984: 178.0662 + 176.0321). In total, sulfates and glucuronides could be detected for 
one aryl-hydroxy isomer (nos. 7S and 7G) and the two isomers of the N-deallyl aryl-hydroxy 
metabolite (nos. 4S, 5S, 4G, and 5G). For the second aryl-hydroxy isomer (no. 8G), only a 
glucuronide could be observed. 
 
7-Me-DALT 
 
Glucuronides of the aryl-hydroxy (no. 18G) and the N-deallyl alkyl-hydroxy metabolite (no. 17G) 
were found, but not their sulfates. The N-deallyl aryl-hydroxy metabolite formed a glucuronide as 
well as a sulfate (nos. 16S and 16G in Fig. S5). Again, after loss of the conjugate moiety (-79.9568 
u for sulfates or -176.0321 u for glucuronides) the spectra showed same fragment ions 
corresponding to those of the underlying phase I metabolites plus fragment ions of m/z 254.0482 
(C11H12O4NS+; no. 16S) or m/z 350.1234 (C17H20O7N+; nos. 16G, 17G, and 18G) for the ethyl 
indole moieties (sections 1+2) still carrying sulfate or glucuronide rests.  
 
5,6-MD-DALT 
 
All conjugates resulted from the demethylenyl metabolite, namely one glucuronide (no. 33G), one 
methyl conjugate (no. 33M in Fig. S6), and one combination of both (no. 33MG). Again, fragment 
ions of the conjugated ethyl indole moieties (section 1+2) were observed of m/z 352.1027 
(C16H18O8N+; no. 33G) or m/z 366.1183 (C17H20O8N+; no. 33MG) in addition to the fragment ions 
described for the underlying phase I metabolite. 
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Metabolic pathways proposed according to mass spectral interpretation 
 
The metabolic pathways proposed according to the identified metabolites are depicted in Fig. 2 for 
5-F-DALT, in Fig. 3 for 7-Me-DALT, and in Fig. 4 for 5,6-MD-DALT. Numbers correspond to 
those shown in Fig. S1-6. 
 
5-F-DALT 
 
Aromatic hydroxylations on the indole ring could be expected at four positions but only two of 
them were detected (7, 8 in Fig. 2). This was most probably caused by either insufficient separation 
or low abundance of the other isomers. These metabolites were further hydroxylated to two 
dihydroxy metabolites (9, 10) and these finally to two trihydroxy metabolites (12, 13) at the indole 
ring, respectively. Furthermore, a ring-rearranged metabolite (6) could be formed after aliphatic 
hydroxylation in section 2. N-Oxidation could only be observed in combination with hydroxylation 
in section 3 (11). N-dealkylation led to metabolite no. 3, which was further hydroxylated in section 
1 to two isomeric N-deallyl hydroxy metabolites (4, 5) and one of them was subsequently 
N-dealkylated to the N,N-bis-deallyl hydroxy metabolite (2). 
 
7-Me-DALT 
 
Aromatic and aliphatic hydroxylations led to two isomeric aryl-hydroxy metabolites (18, 19 in Fig. 
3), which were further aliphatically hydroxylated in section 2 (22) or aromatically in section 1 (23). 
The combination of both led to metabolite no. 26. Further dihydroxylation in section 3 of the 
metabolite no. 23 finally led to a fourfold hydroxylated metabolite carrying two aromatic and two 
aliphatic hydroxy groups (29). N-Oxidation (20) followed by mono- (24) and dihydroxylation (27) 
in section 3 could also be observed. Metabolite no. 15 resulted from N-dealkylation followed by 
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aromatic (16) or aliphatic hydroxylation in section 2 (17). Another pathway was the 
carboxylation after initial hydroxylation of the methyl group in section 1 and subsequent oxidation 
to the carboxylic acid (21). In addition, this step could be followed by aromatic mono- (25) and 
dihydroxylation (28). 
 
5,6-MD-DALT 
 
Only aromatic mono- (35 in Fig. 4) and dihydroxylation (37) could be observed in section 1 but no 
single aliphatic hydroxylation. However, N-oxidation (36) with following mono- (38) and 
dihydroxylation in section 3 (39) could be proposed. In addition, N-dealkylation (31) followed by 
aromatic hydroxylation (32) could be observed as well as O-demethylenation (33), typical for 
demethylenyl structures, which was followed by hydroxylation in section 2 and oxidation to the 
keto or amide group (34). 
 
Incubations of 5-F-DALT, 7-Me-DALT, and 5,6-MD-DALT with human liver microsomes 
 
To confirm whether the metabolites found in rat urine can also be found in human urine, pHLM 
incubations were performed providing a good tool for predictions of phase I metabolites that could 
be detected in human urine as already described in former studies [26, 28-30]. All phase I 
metabolites could be detected with exception of the N,N-bis-deallyl aryl-hydroxy metabolite (no. 2 
in Fig. S1) in the case of 5-F-DALT and of the threefold and fourfold hydroxy metabolites (nos. 23, 
26, 27, and 29 in Fig. S2) in the case of 7-Me-DALT. the demethylenyl oxo metabolite and the 
pathway leading to the N-dealkylation (nos. 31 and 32 in Fig. S3) could not be confirmed for 
5,6-MD-DALT. This fact might be explained by CYP inhibition by 5,6-MD-DALT shown by 
Dinger et al. [31] who investigated the inhibition potential of methylenedioxy-derived designer 
drugs and concluded that 5,6-MD-DALT was a strong inhibitor of CYP1A2, CYP2C9, CYP2D6, 
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and CYP3As. However, it seemed reasonable to assume that at least some of the detected rat 
metabolites might also be found in human urine for all compounds. 
 
Initial screening for determining the CYP activity  
 
The metabolites were detected after incubation with individual CYPs. The general involvement of 
the single CYPs in metabolic pathways of 5-F-DALT is given in Table 1, those of 7-Me-DALT in 
Table 2, and those of 5,6-MD-DALT in Table 3. It should be kept in mind that these qualitative 
data did not reflect a quantitative contribution of a CYP to the hepatic clearance that would require 
the collection of enzyme kinetic data [32], which was beyond the scope of this study. According to 
these findings, the following isoenzymes were generally involved in the given metabolic steps: for 
5-F-DALT, CYP1A2, CYP2B6, CYP2D6, and CYP3A4 in all types of hydroxylations, CYP1A2 
and CYP2D6 in oxidation to the oxo metabolite, CYP 1A2, CYP2C9, CYP2C19, CYP2D6, and 
CYP3A4 in N-dealkylations; for 7-Me-DALT, CYP2B6 and CYP3A4 in all types of hydroxylations, 
CYP2D6 and CYP3A5 in oxidation to the carboxy metabolites, and CYP1A2, CYP2B6, CYP2C9, 
CYP2C19, and CYP3A4 in N-dealkylations; for 5,6-MD-DALT, CYP3A4 in all types of 
hydroxylations, CYP1A2, CYP2C9, and CYP3A4 in demethylenations, and CYP1A2, CYP2C9, 
CYP2D6, and CYP3A4 in N-dealkylations. The inhibition potential of 5,6-MD-DALT on these 
CYPs [31] could be responsible for not detecting the corresponding metabolites in pHLM 
incubations. 
 
GC-MS, LC-MSn, and LC-HR-MS/MS screening for detection of 5-F-DALT, 7-Me-DALT, and 
5,6-MD-DALT  
 
Due to the fact that the investigated compounds did not yet appear on the market, no human doses 
are known. Nevertheless, the known and misused derivative 5-MeO-DALT might be taken into 
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consideration with suggested human doses of about 10 mg [33-35]. After scaling by 
dose-by-factor approach according to Sharma et al. [36], such doses would correspond to 1 mg/kg 
BM administered to rats. The corresponding urine samples were used for the detectability studies. 
As the drug potency might be higher, the expected users’ dose could also be lower than 10 mg. 
Hence, rat urine analysis following drug administration of 0.1 mg/kg BM was included in order to 
verify reliable detection. All targets found in rat urine after 1 or 0.1 mg/kg BM administration using 
GC-MS are given in Table 4 with the corresponding fragment ions, their relative abundances, and 
their retention indices. The targets using LC-MSn are shown in Table 5 with the protonated 
precursor ions, characteristic MS2 and MS3 fragment ions, and retention times. The reference 
spectra for GC-MS and LC-MSn monitoring are published elsewhere [21, 23]. In Table 6, the 
targets using LC-HR-MS/MS are shown in an overview of compounds found in all three SUSAs in 
the two different doses and the corresponding spectra are depicted in supplementary data Figs. 
S1-6. 
In the GC-MS screening, 5-F-DALT and 7-Me-DALT could be detected, but not 
5,6-MD-DALT when administering the 1 mg/kg BM dose. The 0.1 mg/kg BM dose did not allow 
for the detection of the test drugs although they could be monitored after high dose administration 
and might therefore be detectable in overdose cases. The LC-MSn screening allowed detection of all 
drugs after 1 mg/kg BM administrations and only 5-F-DALT enabled monitoring at the 0.1 mg/kg 
BM dose. The LC-HR-MS/MS procedure revealed the ability to monitor all drugs after the 1 mg/kg 
BM doses although only 5-F-DALT and 7-Me-DALT following the 0.1 mg/kg BM doses. Thus, 
5,6-MD-DALT could not be monitored after the 0.1 mg/kg BM dose by the three SUSAs, which 
highlighted a challenge, for example, in cases where this drug would be consumed in such small 
doses.  
The most abundant metabolites following work-up of a rat urine sample after the 1 mg/kg BM 
dose are depicted in Fig. 5 as reconstructed LC-HR-MS ion chromatograms with the given m/z 
values. The most abundant peaks of 5-F-DALT (part A) were the aryl-hydroxy metabolite (7) and 
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the two isomers of the aryl-hydroxy glucuronide (7G and 8G), those of 7-Me-DALT (part B) the 
N-deallyl aryl-hydroxy (16), the carboxy (21), and the aryl-dihydroxy metabolite (23), and those of 
5,6-MD-DALT (part C) the demethylenyl (33), the demethylenyl oxo (34), and the demethylenyl 
glucuronide metabolite (33G). These results showed that a reliance on the parent molecule alone, at 
least when working with urine samples [15] following the investigated doses, might carry the risk 
of providing false negative results without including the targeted analysis of their biotransformation 
products.   
 
 
Conclusions 
 
The three substances 5-F-DALT, 7-Me-DALT, and 5,6-MD-DALT might be considered as possible 
replacements of already misused tryptamine-based NPS in the event of their scheduling. They 
showed an extensive biotransformation in rats. Results obtained from pHLM incubations suggested 
that that most metabolites might also be detectable in human urine. CYP1A2, CYP 2B6, CYP2C9, 
CYP2C19, CYP2D6, CYP3A4, and CYP3A5 were generally involved in the main pathways. 
GC-MS did not allow a reliable monitoring of suspected consumption although it is suspected that 
this should be overcome in the event of larger doses or overdose cases. The LC-MSn and 
LC-HR-MS/MS SUSAs were suitable for monitoring consumption of all three compounds, but only 
via their metabolites. Very low doses administered to male Wistar rats (0.1 mg/kg BM) revealed the 
ability of LC-HR-MS/MS to monitor 5-F-DALT and 7-Me-DALT, whereas 5-F-DALT could be 
monitored using LC-MSn. However, when a 1 mg/kg BM dose was administered, all drugs could be 
monitored by LC-HR-MS/MS and LC-MSn. 
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Table 1 General involvement of human CYP isoenzymes in metabolic pathways of 5-F-DALT  
CYP isoenzyme Hydroxylation,  
all types 
Oxidation to oxo 
metabolites 
N-dealkylation 
CYP1A2 + + + 
CYP2A6    
CYP2B6 +   
CYP2C8    
CYP2C9   + 
CYP2C19   + 
CYP2D6 + + + 
CYP2E1    
CYP3A4 +  + 
CYP3A5    
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Table 2 General involvement of human CYP isoenzymes in metabolic pathways of 7-Me-DALT  
CYP isoenzyme Hydroxylation,  
all types 
Oxidation to carboxy 
metabolites 
N-dealkylation 
CYP1A2   + 
CYP2A6    
CYP2B6 +  + 
CYP2C8    
CYP2C9   + 
CYP2C19   + 
CYP2D6  +  
CYP2E1    
CYP3A4 +  + 
CYP3A5  +  
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Table 3 General involvement of human CYP isoenzymes in metabolic pathways of 
5,6-MD-DALT  
CYP isoenzyme Hydroxylation,  
all types 
Demethylenation N-dealkylation 
CYP1A2  + + 
CYP2A6    
CYP2B6    
CYP2C8    
CYP2C9  + + 
CYP2C19    
CYP2D6   + 
CYP2E1    
CYP3A4 + + + 
CYP3A5    
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Table 4 Targets for GC-MS SUSA monitoring 5-F-DALT and 7-Me-DALT with molecular 
masses, five most abundant fragment ions, their relative abundances, and retention indices 
according to Kovats [37], numbering according to Fig. 2-4 
No. Target for SUSA Molecular 
mass, u 
GC-MS fragment ions, m/z, and their 
relative intensities, % 
Retention 
index 
7/8 5-F-DALT-M (HO-aryl-) AC 316 110 (100), 164 (7), 68 (4), 81 (3), 178 (3) 2300 
18/19 7-Me-DALT-M (HO-aryl-) AC 312 110 (100), 160 (10), 159 (4), 130 (4), 283 
(3) 
2450 
3 7-Me-DALT-M 
(N-dealkyl-HO-aryl-) 2AC 
314 173 (100), 215 (62), 160 (55), 70 (30), 202 
(25) 
2630 
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Table 5 Targets for LC-MSn SUSA monitoring 5-F-DALT, 7-Me-DALT, and 5,6-MD-DALT 
with protonated precursor ions, characteristic MS2 and MS3 fragment ions, and retention times (RT), 
numbering according to Fig. 2-4 
No. Target for SUSA Precursor 
ion, m/z 
MS2 fragment ions, 
m/z, and relative 
intensities, % 
MS3 fragment ions, 
m/z, and relative 
intensities, %  
RT, 
min 
4 5-F-DALT-M 
(N-dealkyl-HO-aryl-) isomer 1 
235 178 (100), 166 (82), 70 
(3) 
178: 130 (100), 150 
(76), 103 (36), 178 
(30), 134 (14) 
5.2 
5 5-F-DALT-M 
(N-dealkyl-HO-aryl-) isomer 2 
235 178 (100), 166 (6) 178: 150 (100), 130 
(20), 178 (11), 151 
(11), 133 (10) 
6.8 
6 5-F-DALT-M 
(oxo-) 
273 232 (100) 232: 191 (100) 10.1 
7 5-F-DALT-M 
(HO-aryl-) isomer 1 
275 110 (100), 178 (5), 233 
(1) 
110: 81 (100), 68 (53), 
79 (25), 71 (13), 56 
(11) 
7.2 
8 5-F-DALT-M 
(HO-aryl-) isomer 2 
275 178 (100), 110 (76), 98 
(10), 239 (2), 233 (2) 
178: 178 (100), 123 
(92), 150 (67), 130 
(45), 140 (33) 
9.2 
4G 5-F-DALT-M 
(N-dealkyl-HO-aryl-glucuronide) 
isomer 1 
411 354 (100), 166 (76), 
178 (36), 235 (13), 342 
(12) 
354: 178 (100), 158 
(2), 130 (2), 150 (1) 
3.0 
5G 5-F-DALT-M 
(N-dealkyl-HO-aryl-glucuronide) 
isomer 2 
411 354 (100), 178 (52), 
235 (41), 342 (11), 150 
(5) 
354: 178 (100) 5.0 
7G 5-F-DALT-M 
(HO-aryl-glucuronide) isomer 1 
451 354 (100), 275 (81), 
321 (66), 391 (35), 178 
(27) 
- 4.5 
8G 5-F-DALT-M 
(HO-aryl-glucuronide) isomer 2 
451 354 (100), 178 (52), 
275 (47), 416 (13), 394 
(7) 
- 4.8 
16 7-Me-DALT-M 
(N-dealkyl-HO-aryl-) 
231 350 (100), 162 (91), 
338 (53), 174 (47), 231 
(33) 
350: 174 (100), 159 
(3), 146 (1) 
5.2 
21 7-Me-DALT-M 
(carboxy-) 
285 188 (100), 110 (93), 
170 (17), 207 (8), 189 
(5) 
188: 142 (100), 160 
(25), 143 (14), 162 
(13), 170 (9) 
9.5 
23 7-Me-DALT-M 
(di-HO-aryl-) 
287 190 (100), 245 (57), 
110 (30), 162 (27), 251 
(19) 
190: 162 (100), 163 
(9), 145 (8), 190 (3), 
148 (2) 
7.2 
26 7-Me-DALT-M 
(HO-alkyl-di-HO-aryl-) 
303 110 (100), 261 (4), 206 
(3), 257 (3), 267 (2) 
110: 81 (100), 80 (79), 
67 (62), 77 (58), 68 
4.9 
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No. Target for SUSA Precursor 
ion, m/z 
MS2 fragment ions, 
m/z, and relative 
intensities, % 
MS3 fragment ions, 
m/z, and relative 
intensities, %  
RT, 
min 
(28) 
29 7-Me-DALT-M 
(di-HO-alkyl-di-HO-aryl-) 
319 144 (100), 188 (82), 
132 (27), 170 (23), 155 
(2) 
144: 84 (100), 71 (1) 6.9 
16G 7-Me-DALT-M 
(N-dealkyl-HO-aryl-glucuronide) 
407 350 (100), 162 (91), 
338 (53), 174 (47), 231 
(33) 
350: 174 (100), 159 
(3), 146 (1) 
3.5 
17G 7-Me-DALT-M 
(N-dealkyl-HO-alkyl-glucuronide) 
407 350 (100), 231 (83), 
174 (61), 156 (49), 144 
(20) 
350: 156 (100), 174 
(45), 154 (2), 129 (1) 
5.8 
18G 7-Me-DALT-M 
(HO-aryl-glucuronide) 
447 350 (100), 271 (32), 
148 (5), 324 (3), 174 
(3) 
350: 174 (100), 175 (2) 5.0 
38 5,6-MD-DALT-M 
(N-oxide-HO-alkyl-) 
317 142 (100), 188 (16), 
100 (3) 
142: 100 (100), 84 
(58), 83 (7), 71 (3), 74 
(2) 
8.1 
33G 5,6-MD-DALT-M 
(demethylenyl-glucuronide) 
449 352 (100), 273 (4), 176 
(3), 130 (1) 
352: 176 (100), 158 
(7), 130 (1), 237 (1) 
4.4 
33MG 5,6-MD-DALT-M 
(demethylenyl-methyl-glucuronide) 
463 287 (100), 366 (16), 
190 (13), 158 (3), 418 
(2) 
287: 110 (100), 190 
(13), 193 (1) 
4.7 
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Table 6 Compounds for SUSA using GC-MS, LC-MSn, and LC-HR-MS/MS monitoring 
5-F-DALT, 7-Me-DALT, and 5,6-MD-DALT after doses of 1 or 0.1 mg/kg BM administered to rat, 
brackets indicate unclear isomer, numbering according to Fig. 2-4 
No. Compound for SUSA GC-MS LC-MSn LC-HR-MS/MS 
  0.1 1 0.1 1 0.1 1 
4 5-F-DALT-M  
(N-dealkyl-HO-aryl-) isomer 1 
  + + + + 
5 5-F-DALT-M  
(N-dealkyl-HO-aryl-) isomer 2 
   +  + 
6 5-F-DALT-M  
(oxo-) 
  + + + + 
7 5-F-DALT-M  
(HO-aryl-) isomer 1 
 + + + + + 
8 5-F-DALT-M  
(HO-aryl-) isomer 2 
   +  + 
11 5-F-DALT-M  
(N-oxide-HO-alkyl-) 
     + 
4S 5-F-DALT-M  
(N-dealkyl-HO-aryl-sulfate) isomer 1 
     + 
5S 5-F-DALT-M  
(N-dealkyl-HO-aryl-sulfate) isomer 2 
     + 
7S 5-F-DALT-M  
(HO-aryl-sulfate) 
     + 
4G 5-F-DALT-M  
(N-dealkyl-HO-aryl-glucuronide) isomer 1 
   +  + 
5G 5-F-DALT-M  
(N-dealkyl-HO-aryl-glucuronide) isomer 2 
   +  + 
7G 5-F-DALT-M  
(HO-aryl-glucuronide) isomer 1 
   +  + 
8G 5-F-DALT-M  
(HO-aryl-glucuronide) isomer 2 
   +  + 
16 7-Me-DALT-M  
(N-dealkyl-HO-aryl-) 
 +  + + + 
17 7-Me-DALT-M  
(N-dealkyl-HO-alkyl-) 
     + 
18 7-Me-DALT-M  
(HO-aryl-) isomer 1 
 +    + 
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No. Compound for SUSA GC-MS LC-MSn LC-HR-MS/MS 
  0.1 1 0.1 1 0.1 1 
19 7-Me-DALT-M  
(HO-aryl-) isomer 2 
     + 
21 7-Me-DALT-M  
(carboxy-) 
   +  + 
23 7-Me-DALT-M  
(di-HO-aryl-) 
   +  + 
24 7-Me-DALT-M  
(N-oxide-HO-alkyl-) 
     + 
25 7-Me-DALT-M  
(HO-aryl-carboxy) 
     + 
26 7-Me-DALT-M  
(HO-alkyl-di-HO-aryl-) 
   +  + 
28 7-Me-DALT-M  
(di-HO-aryl-carboxy) 
     + 
29 7-Me-DALT-M  
(di-HO-alkyl-di-HO-aryl-) 
   +  + 
16S 7-Me-DALT-M  
(N-dealkyl-HO-aryl-sulfate) 
     + 
16G 7-Me-DALT-M  
(N-dealkyl-HO-aryl-glucuronide) 
   + + + 
17G 7-Me-DALT-M  
(N-dealkyl-HO-alkyl-glucuronide) 
   +  + 
18G 7-Me-DALT-M  
(HO-aryl-glucuronide) 
   +  + 
33 5,6-MD-DALT-M  
(demethylenyl-) 
     + 
34 5,6-MD-DALT-M  
(demethylenyl-oxo-) 
     + 
38 5,6-MD-DALT-M  
(N-oxide-HO-alkyl-) 
   +  + 
33G 5,6-MD-DALT-M  
(demethylenyl-glucuronide) 
   +  + 
33MG 5,6-MD-DALT-M  
(demethylenyl-methyl-glucuronide) 
   +  + 
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Legends to Figures 
 
Fig. 1 Structure of 5-F-DALT (part A), 7-Me-DALT (part B), and 5,6-MD-DALT (part C) with 
corresponding division into sections to aid the identification procedure of metabolites 
 
Fig. 2 Proposed metabolic pathways for 5-F-DALT (numbering according to Fig. S1) 
 
Fig. 3 Proposed metabolic pathways for 7-Me-DALT (numbering according to Fig. S2) 
 
Fig. 4 Proposed metabolic pathways for 5,6-MD-DALT (numbering according to Fig. S3) 
 
Fig. 5 Reconstructed LC-HR-MS ion chromatograms with the corresponding protonated molecular 
exact masses (± 5 ppm) indicating 5-F-DALT (part A), 7-Me-DALT (part B), or 5,6-MD-DALT 
metabolites (part C) in rat urine samples after 1 mg/kg BM low dose administration (numbering 
according to Fig. S1-3) 
 
For Peer Review
  
 
 
Fig. 1 Structure of 5-F-DALT (part A), 7-Me-DALT (part B), and 5,6-MD-DALT (part C) with corresponding 
division into sections to aid the identification procedure of metabolites  
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Fig. 2 Proposed metabolic pathways for 5-F-DALT (numbering according to Fig. S1)  
 
126x57mm (300 x 300 DPI)  
 
 
Page 41 of 59 Analytical & Bioanalytical Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Fig. 3 Proposed metabolic pathways for 7-Me-DALT (numbering according to Fig. S2)  
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Fig. 4 Proposed metabolic pathways for 5,6-MD-DALT (numbering according to Fig. S3)  
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Fig. 5 Reconstructed LC-HR-MS ion chromatograms with the corresponding protonated molecular exact 
masses (± 5 ppm) indicating 5-F-DALT (part A), 7-Me-DALT (part B), or 5,6-MD-DALT metabolites (part C) 
in rat urine samples after 1 mg/kg BM low dose administration (numbering according to Fig. S1-3)  
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Fig. S1 LC-HR-MS/MS spectra of 5-F-DALT and its phase I metabolites arranged according to their precursor 
values, proposed chemical structures, accurate masses, calculated elemental formulas, mass error values in parts 
per million (ppm), and retention times in minutes (min) 
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Fig. S2 LC-HR-MS/MS spectra of 7-Me-DALT and its phase I metabolites arranged according to their 
precursor values, proposed chemical structures, accurate masses, calculated elemental formulas, mass error 
values in parts per million (ppm), and retention times in minutes (min) 
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Fig. S3 LC-HR-MS/MS spectra of 5,6-MD-DALT and its phase I metabolites arranged according to their 
precursor values, proposed chemical structures, accurate masses, calculated elemental formulas, mass error 
values in parts per million (ppm), and retention times in minutes (min) 
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Fig. S4 LC-HR-MS/MS spectra of 5-F-DALT phase II metabolites arranged according to their precursor 
values, proposed chemical structures, accurate masses, calculated elemental formulas, mass error values in parts 
per million (ppm), and retention times in minutes (min) 
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Fig. S5 LC-HR-MS/MS spectra of 7-Me-DALT phase II metabolites arranged according to their precursor 
values, proposed chemical structures, accurate masses, calculated elemental formulas, mass error values in parts 
per million (ppm), and retention times in minutes (min) 
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Fig. S6 LC-HR-MS/MS spectra of 5,6-MD-DALT phase II metabolites arranged according to their precursor 
values, proposed chemical structures, accurate masses, calculated elemental formulas, mass error values in parts 
per million (ppm), and retention times in minutes (min) 
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